[Treatment of lymphangiomas with picibanil in the first year of life]

Subotic, U; Hosie, S; Waag, K L; Reinshagen, K (2008). [Treatment of lymphangiomas with picibanil in the first year of life]. Klinische Pädiatrie, 220(4), pp. 248-52. Stuttgart: Thieme 10.1055/s-2008-1073158

Full text not available from this repository. (Request a copy)

BACKGROUND: The therapeutic gold standard of cystic hygroma is its complete resection. Because of its growth pattern and its main location in the head and neck region complete resection is not always possible. An alternative is the local injection of Picibanil, but only few cases have been published about its use in infants. PATIENTS/METHOD: We retrospectively analyzed the data of 8 infants (age: 2 weeks-12 months) who got Picibanil therapy because of cystic hygroma in the time period 2002 until 2006. Follow up ranged from 3 months up to 3 years. RESULTS: During the postoperative period all patients had local swelling, in 4 cases accompanied with local inflammation and fever. Tumor reduction of >50% was obtained in 7 of 8 patients. CONCLUSIONS: Local injection of Picibanil in infants with cystic hygroma seems to be a safe alternative to surgical therapy, especially when complete tumor resection means damage of important neighbouring structures. Prospective trials are necessary to confirm the better outcome after therapy with Picibanil compare to primary surgery.

Item Type:	Journal Article (Further Contribution)
Division/Institute:	04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Paediatric Surgery
UniBE Contributor:	Subotic, Ulrike
ISSN:	1439-3824
ISBN:	18654945
Publisher:	Thieme
Language:	English
Submitter:	Factscience Import
Date Deposited:	04 Oct 2013 15:06
Last Modified:	05 Dec 2022 14:20
Publisher DOI:	10.1055/s-2008-1073158
PubMed ID:	18654945
Web of Science ID:	000258458200007
URI:	https://boris.unibe.ch/id/eprint/28704 (FactScience: 126098)